Article Text

This article has a correction. Please see:

other Versions

PDF
Extended report
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
  1. J L Nam1,
  2. K L Winthrop2,
  3. R F van Vollenhoven3,
  4. K Pavelka4,
  5. G Valesini5,
  6. E M A Hensor1,
  7. G Worthy6,
  8. R Landewé7,
  9. J S Smolen8,
  10. P Emery1,
  11. M H Buch1
  1. 1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
  2. 2Oregon Health and Science University, Portland, Oregon, USA
  3. 3Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden
  4. 4Institute of Rheumatology and Clinic of Rheumatology Charles University, Prague, Czech Republic
  5. 5Rheumatology Unit, Department of Clinical Medicine and Medical Therapy, Sapienza Università di Roma, Reumatologia, Policlinico Umberto I, Rome, Italy
  6. 6Clinical Trials Research Unit, University of Leeds, Leeds, UK
  7. 7Maastricht University Medical Center and CAPHRI Research Institute, Maastricht, The Netherlands
  8. 8Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
  1. Correspondence to Dr Maya H Buch, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK; m.buch{at}leeds.ac.uk

Abstract

Objectives To review the evidence for the efficacy and safety of biological agents in patients with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the European League Against Rheumatism (EULAR) Task Force.

Methods Medline, Embase and Cochrane databases were searched for relevant articles on infliximab (IFX), etanercept (ETN), adalimumab (ADA), certolizumab-pegol (CZP), golimumab (GLM), anakinra (ANA), abatacept (ABT), rituximab (RTX) and tocilizumab (TCZ) published between 1962 and February 2009; published abstracts from the 2007–2008 American College of Rheumatology (ACR) and EULAR conference were obtained.

Results 87 articles and 40 abstracts were identified. In methotrexate (MTX) naïve patients, biological therapy with IFX, ETN, ADA, GLM or ABT has been shown to improve clinical outcomes (1B). In MTX/other synthetic disease-modifying antirheumatic drug (DMARD) failures all nine biological agents confer benefit (1B), with lower efficacy noted for ANA. RTX, ABT, TCZ and GLM demonstrate efficacy in tumour necrosis factor inhibitor (TNFi) failures (1B). Less evidence exists for switching between IFX, ETN and ADA (3B). Biological and MTX combination therapy is more efficacious than a biological agent alone (1B). A safety review shows no increased malignancy risk compared with conventional DMARDs (3B). TNFi are generally associated with an increased risk of serious bacterial infection, particularly within the first 6 months of treatment initiation; increased tuberculosis (TB) rates with TNFi are highest with the monoclonal antibodies (3B).

Conclusions There is good evidence for the efficacy of biological agents in patients with RA. Safety data confirm an increased risk of bacterial infection and TB with TNFi compared with conventional DMARDs.

Statistics from Altmetric.com

Footnotes

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Competing interests None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism